Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS

Organogenesis Holdings released its Q1 2026 earnings on May 7, 2026, reporting an EPS of -$0.37, which missed the consensus estimate of -$0.29 by $0.08, MarketBeat as of May 2026. Quarterly revenue came in at $37.23 million, below analysts' expectations of $43.26 million. The stock traded at $2.33 on May 11, 2026 on Nasdaq, down 1.69% from the prior close, StockInvest.us as of 05/11/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Organogenesis Holdings: core business model

Organogenesis Holdings develops and markets solutions for the advanced wound care and surgical biologics markets. The company focuses on regenerative medicine products, including tissue-engineered skin substitutes and wound care therapies primarily used in the treatment of chronic and acute wounds. These products are sold to healthcare providers in the United States, with a presence in North American markets. The business model relies on innovation in biologics to address unmet needs in wound healing and tissue repair.

Main revenue and product drivers for Organogenesis Holdings

Key products include Apligraf and PuraPly, which are human skin substitutes and wound care dressings generating the majority of revenue. In Q1 2026, reported revenue of $37.23 million reflected demand in advanced wound care, though it fell short of expectations published as of May 7, 2026, MarketBeat as of May 2026. Trailing twelve-month EPS stood at -$0.19 as of the latest report. The company maintains a market cap of approximately $304.96 million, with shares at $2.37 noted in recent data, WallStreetZen as of 2026.

Industry trends and competitive position

The advanced wound care segment benefits from rising demand due to aging populations and increasing prevalence of chronic wounds like diabetic foot ulcers in the US. Organogenesis competes with players in regenerative biologics, holding a position in specialty generics with EBITDA of $35.99 million reported for the period ending in recent filings, per WallStreetZen as of 2026. US investors track this space for exposure to healthcare innovation amid sector growth.

Why Organogenesis Holdings matters for US investors

Listed on Nasdaq, Organogenesis provides US investors direct access to regenerative medicine advancements addressing domestic healthcare needs, such as wound care for an aging population. Its products support hospitals and clinics nationwide, tying into broader US medical spending trends.

Conclusion

Organogenesis Holdings' Q1 2026 results showed revenue and EPS misses amid ongoing operations in advanced wound care. The stock has experienced volatility, trading at $2.33 on May 11, 2026 on Nasdaq. Investors monitor regenerative medicine developments for potential in the US healthcare market. Market dynamics and future quarters will shape the trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.